<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01991561</url>
  </required_header>
  <id_info>
    <org_study_id>CP-H5VLP-005</org_study_id>
    <nct_id>NCT01991561</nct_id>
  </id_info>
  <brief_title>Immunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine.</brief_title>
  <official_title>Immunogenicity, Safety, Tolerability of a Plant-made H5 VLP Influenza Vaccine.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicago</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2, Randomized, Observer-blind, Multicenter, Dose-Ranging Study to Evaluate the&#xD;
      Immunogenicity, Safety, and Tolerability of the plant-made H5 VLP Influenza vaccine&#xD;
      adjuvanted with Alhydrogel or Glucopyranosyl-lipid adjuvant in squalene emulsion (GLA-SE), in&#xD;
      healthy adults 18-60 years of age.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will consist of a dose-ranging in 390 subjects who will be randomized to receive&#xD;
      one injection at Days 0 and 21 of either a low, medium or a high dose of H5 VLP Influenza&#xD;
      vaccine combined with Alhydrogel®, or a low or high dose of H5 VLP Influenza vaccine combined&#xD;
      with GLA-SE, or the placebo preparation (100 millimolar (mM) phosphate buffer + 150 mM Sodium&#xD;
      Chloride (NaCl) + 0.01% Tween 80). Seven-day (7) safety data after the first immunization of&#xD;
      the first 25% study subjects enrolled (98 subjects) will be tabulated and reviewed by the&#xD;
      Data and Safety Monitoring Board (DSMB), prior to permitting the first immunization of the&#xD;
      remaining study subjects and the second immunisations. Also, based on medical expert opinion&#xD;
      and on safety criteria defined in the protocol, a DSMB review might be necessary on the&#xD;
      seven-day safety data of the same 25% study subjects following administration of their second&#xD;
      dose, before proceeding to the second immunizations of the remaining study subjects.&#xD;
      Twenty-one (21) days after each immunization, key safety and immunogenicity data will be&#xD;
      collected and analysed. All subjects will be followed for safety until Day 407.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Levels of antibodies induced against the H5 of the H5N1/A/Indonesia/5/05, clade 2.1 virus</measure>
    <time_frame>21 days after each injection</time_frame>
    <description>Immunogenicity Geometric mean titers (GMTs) of hemagglutination inhibition (HI antibody on Day 21).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Levels of antibodies induced against the H5 of the H5N1/A/Indonesia/5/05, clade 2.1 virus</measure>
    <time_frame>42 days after each injection</time_frame>
    <description>Immunogenicity Geometric mean titers (GMTs) of hemagglutination inhibition (HI antibody on Day 42).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cross-reactivity of antibodies induced by 2 consecutive doses of H5 VLP influenza vaccine</measure>
    <time_frame>21 days after each injection</time_frame>
    <description>Measures of Geometric Mean Fold Rise, seroconversion rate and seroprotection rate (for HI only).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactivity of antibodies induced by 2 consecutive doses of H5 VLP influenza vaccine given 21 days apart</measure>
    <time_frame>21 days after each injection</time_frame>
    <description>GMFR, seroconversion rate, percentage of subjects with a detectable MN antibody response</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">390</enrollment>
  <condition>Virus Diseases</condition>
  <condition>RNA Virus Infections</condition>
  <condition>Respiratory Tract Diseases</condition>
  <condition>Respiratory Tract Infections</condition>
  <arm_group>
    <arm_group_label>Low dose of H5 VLP vaccine + Alhydrogel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with Alhydrogel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Med dose H5 VLP vaccine + Alhydrogel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological:Med dose of H5 VLP vaccine + Alhydrogel, 2 doses given 21 days apart of Med dose H5 VLP vaccine mixed with Alhydrogel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose of H5 VLP vaccine + Alhydrogel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with Alhydrogel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose of H5 VLP vaccine + GLA-SE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with GLA-SE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose of H5 VLP vaccine + GLA-SE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with GLA-SE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo comparator: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Biological: Placebo 2 doses given 21 days apart of the placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Low dose of H5 VLP vaccine + Alhydrogel</intervention_name>
    <description>Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with Alhydrogel</description>
    <arm_group_label>Low dose of H5 VLP vaccine + Alhydrogel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Med dose of H5 VLP vaccine + Alhydrogel</intervention_name>
    <description>Biological:Med dose of H5 VLP vaccine 2 doses given 21 days apart of Med dose H5 VLP vaccine mixed with Alhydrogel</description>
    <arm_group_label>Med dose H5 VLP vaccine + Alhydrogel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High dose of H5 VLP vaccine + Alhydrogel</intervention_name>
    <description>Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with Alhydrogel</description>
    <arm_group_label>High dose of H5 VLP vaccine + Alhydrogel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Low dose of H5 VLP vaccine + GLA-SE</intervention_name>
    <description>Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with GLA-SE</description>
    <arm_group_label>Low dose of H5 VLP vaccine + GLA-SE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High dose of H5 VLP vaccine + GLA-SE</intervention_name>
    <description>Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with GLA-SE</description>
    <arm_group_label>High dose of H5 VLP vaccine + GLA-SE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo comparator: Placebo</intervention_name>
    <description>Biological: Placebo 2 doses given 21 days apart of the placebo</description>
    <arm_group_label>Placebo comparator: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female adults, 18 to 60 years of age, inclusive&#xD;
&#xD;
          2. Healthy as judged by the Investigator and determined by medical history,&#xD;
             history/symptom-directed physical examination, vital signs, screening laboratories and&#xD;
             medical history conducted no more than 30 days prior to study vaccine administration;&#xD;
&#xD;
          3. BMI of ≥18 and ≤ 32;&#xD;
&#xD;
          4. Comprehension of the study requirements, expressed availability for the required study&#xD;
             period and ability to attend scheduled visits;&#xD;
&#xD;
          5. Accessible by telephone on a regular basis;&#xD;
&#xD;
          6. In the opinion of the Investigator, ability and willingness to provide written,&#xD;
             informed consent for participation after reading the informed consent form. The&#xD;
             subject must have adequate opportunity to discuss the study with an Investigator or&#xD;
             qualified designee;&#xD;
&#xD;
          7. If female, have a negative serum pregnancy test result at study entry, and if capable&#xD;
             of child bearing has been consistently using effective birth control for the 28 days&#xD;
             prior to study entry and agree to continue employing adequate birth control measures&#xD;
             for the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of significant acute or chronic, uncontrolled medical or neuropsychiatric&#xD;
             illness. &quot;Uncontrolled&quot; is defined as:&#xD;
&#xD;
               1. Requiring a new medical or surgical treatment within one month prior to study&#xD;
                  vaccine administration;&#xD;
&#xD;
               2. Requiring a change in medication dosage in one month prior to test article&#xD;
                  administration due to uncontrolled symptoms or drug toxicity (elective dosage&#xD;
                  adjustments in stable subjects are acceptable), or&#xD;
&#xD;
               3. Hospitalization or an event fulfilling the definition of a serious adverse event&#xD;
                  within one month prior to test article administration;&#xD;
&#xD;
          2. Any medical or neuropsychiatric condition which, in the Investigator's opinion, would&#xD;
             render the subject unable to provide informed consent or unable to provide valid&#xD;
             safety observations and reporting;&#xD;
&#xD;
          3. Any confirmed or suspected immunosuppressive condition or immunodeficiency including&#xD;
             history of human immunodeficiency virus (HIV) infection or Hepatitis B or C or&#xD;
             presence of lymphoproliferative disease;&#xD;
&#xD;
          4. Presence of any febrile illness, oral temperature of &gt;38.0˚C within 24 hours of test&#xD;
             article administration. Such subjects may be re-evaluated for enrolment after&#xD;
             resolution of illness;&#xD;
&#xD;
          5. History of autoimmune disease;&#xD;
&#xD;
          6. Administration of any vaccine (including any other influenza vaccine) within a 30 day&#xD;
             period prior to study enrolment, or planned administration within the period from the&#xD;
             first vaccination up to blood sampling at Day 42 or within 30 days prior to blood&#xD;
             sampling at Day 228. Immunization on an emergency basis of a tetanus and diphtheria&#xD;
             toxoids adsorbed for adult use (Td) will be allowed provided the vaccine is not&#xD;
             administered within two weeks prior to test article administration. Receipt of any&#xD;
             other emergency immunizations (e.g. rabies) will result in a case-by-case review of&#xD;
             continued participation;&#xD;
&#xD;
          7. Use of any investigational or non-registered product within 30 days prior to study&#xD;
             enrolment or planned use during the study period. Subjects may not participate in any&#xD;
             other drug study while participating in this study;&#xD;
&#xD;
          8. Treatment with systemic glucocorticoids at a dose exceeding ≥ 10 mg of prednisone per&#xD;
             day, or equivalent for more than 7 consecutive days or for 10 or more days in total,&#xD;
             within one month of first test article administration, or any other cytotoxic or&#xD;
             immunosuppressant drug or any immune globulin preparation within three months of&#xD;
             vaccination. Nasal or inhaled glucocorticoids are allowed;&#xD;
&#xD;
          9. Any significant disorder of coagulation or treatment with Coumadin derivatives or&#xD;
             heparin. Persons receiving prophylactic anti-platelet medications, e.g., low-dose&#xD;
             aspirin, and without a clinically apparent bleeding tendency are eligible;&#xD;
&#xD;
         10. History of previous H5N1 vaccination or a history of exposure to H5N1 virus. Any&#xD;
             subject that was enrolled on our previous H5 studies (except the ones that received&#xD;
             placebo) would not be eligible;&#xD;
&#xD;
         11. Are at high risk of contracting H5N1 influenza infection (e.g. poultry workers);&#xD;
&#xD;
         12. History of allergy to any of the constituents of H5 VLP (H5N1) study vaccine,&#xD;
             Alhydrogel® (aluminum hydroxide), GLA-SE, or the phosphate buffer;&#xD;
&#xD;
         13. History of severe allergic reactions (including anaphylaxis) to any food, medication,&#xD;
             or bee sting or previous status of asthmatic;&#xD;
&#xD;
         14. History of tobacco allergy;&#xD;
&#xD;
         15. History of egg allergy (). GLA-SE contains egg phosphatidylcholine.&#xD;
&#xD;
         16. Continuous use of anti-histamines in last 4 weeks prior to immunization and use of&#xD;
             antihistamine in last 48 hours prior to immunization;&#xD;
&#xD;
         17. Have a rash, dermatological condition or tattoos or a muscle mass condition at the&#xD;
             injection site that may interfere with injection site reaction rating. ;&#xD;
&#xD;
         18. Have received a blood transfusion or immunoglobulins within 90 days of study entry;&#xD;
&#xD;
         19. If female, and of childbearing potential, has not been consistently using effective&#xD;
             birth control for the 28 days prior to study entry. An example of highly effective&#xD;
             birth control is oral contraceptives, hormone implants, abstinence (self-reported), or&#xD;
             male condom plus spermicide. All female subjects, regardless of birth control history&#xD;
             must provide a serum sample for pregnancy screening. Effective birth control must be&#xD;
             used for the duration of the study for female of child bearing potential. The subject&#xD;
             must have no plan to become pregnant during the study period;&#xD;
&#xD;
         20. Among female subjects, either known pregnancy or urine beta-human chorionic&#xD;
             gonadotropin (ß-hCG) test results consistent with pregnancy prior to test article&#xD;
             administration on Day 0 and 21;&#xD;
&#xD;
         21. Female subjects who are lactating;&#xD;
&#xD;
         22. Vital sign abnormalities: systolic blood pressure &gt;150 mmHg, diastolic blood pressure&#xD;
             &gt;90 mmHg, resting pulse rate &lt;40 bpm or &gt;100 bpm or according to the Investigator's&#xD;
             opinion;&#xD;
&#xD;
         23. Cancer or treatment for cancer within 3 years of test article administration. Persons&#xD;
             with a history of cancer who are disease-free without treatment for 3 years or more&#xD;
             are eligible. Persons with treated and uncomplicated basal cell carcinoma of the skin&#xD;
             are eligible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Libman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MUHC-Vaccine Study Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis Robles, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Syneos Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>INC Research</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5V2T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUHC Vaccine Study Center</name>
      <address>
        <city>Pierrefonds</city>
        <state>Quebec</state>
        <zip>H9H4Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>September 18, 2013</study_first_submitted>
  <study_first_submitted_qc>November 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza, Human</keyword>
  <keyword>RNA Virus Infections</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>Respiratory Tract Infections</keyword>
  <keyword>Aluminum Hydroxide</keyword>
  <keyword>Adjuvants, Immunologic</keyword>
  <keyword>Immunogenic Factors</keyword>
  <keyword>GLA-SE</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Virus Diseases</keyword>
  <keyword>Orthomyxoviridae Infections</keyword>
  <keyword>Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>RNA Virus Infections</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aluminum Hydroxide</mesh_term>
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

